Submit RFP/RFI
Submit RFP/RFI
Search
Submit RFP/RFI
Submit RFP/RFI
Search
Submit RFP/RFI
Submit RFP/RFI
Search

Confronting the emergence of drug-resistant HIV type 1: Impact of antiretroviral therapy on individual and population resistance

Daar ES, Richman DD
AIDS Research and Human Retroviruses
HGDS
12/31/2004
Publication

Related insights

The Lean Team Playbook: How small biotechs can nail ICH E6(R3) without a large QA team

You’re responsible for showing risk oversight, protocol clarity, and a site-friendly design—but you’ve got a lean team,

Read More
Blog
The R3 Timewarp Redemption: Preventable risks and how to avoid them in a trial

Picture this: a complex trial is running, but it has been plagued with issues from the start.

Read More
Guides
The MythBusters Revelations: Debunking compliance myths to keep your trial on track

ICH E6(R3) is here, and with it, clinical teams are bracing for the impacts. Biotechs are being

Read More
Blog
The Site Cohesion Hypothesis: 3 examples of the impact of CRO site relationships

Behind every enrollment milestone is a web of relationships—some strong, some strained, and some that make all

Read More
Case Study
The Site Stickiness Hypothesis: Good site relationships pay dividends

Every CRO claims to value sites. But the true nature of their site relationships could determine the

Read More
Guides
Reform of the European Union Pharmaceutical Legislation (Adoption Stage TBD)
On 26 April 2023, the European Commission (EC) proposed reforming the European Union (EU) pharmaceutical legislation. This
Read More
Blog
Scroll to Top